Cardiology Pharmacy Specialty Review Course for Recertification + RECERT EXAM Package (Cert # L199282)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 05/29/2019
Content Release Date: 06/26/2019
Expiration Date: 12/17/2019
Activity Type: Application-based
CE Credits: 26 hours (BPS and ACPE)
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists

The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

 

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in cardiology pharmacy.

Activity Overview

This course is intended for BCCPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

  • Review pertinent clinical topics and practice skills
  • List valuable resources for further self-study 

This online course consists of 17 activities (see table below) and provides up to 26 hours of continuing pharmacy education credit and/or recertification credit.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 26 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Cardiology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/en/catalog/cards-review   

These activities are part of the ACCP and  ASHP professional development program for BCCP recertification approved by the BPS. 

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

 

 

Learning Activity

ACPE Number

Credit

Hours

*Assessment Pass Point

Primary Prevention of Cardiovascular Disease
and Public Health (Chapter 1)

0217-9999-19-106-H01-P

1.5

78%

Dyslipidemia (Chapter 2)

0217-9999-19-107-H01-P

1.5

Blood Pressure Management of Adult Patients (Chapter 3)

0217-9999-19-108-H01-P

1.5

Group 1 Assessment

4.5

 

Stable Atherosclerotic Disease (Chapter 4)

0217-9999-19-109-H01-P

1.5

77%

Anticoagulation (Chapter 5)

0217-9999-19-110-H01-P

1.5

Group 2 Assessment

3.00

 

Arrhythmias (Chapter 6)

0217-9999-19-111-H01-P

2.00

73%

Drug Induced Cardiovascular Disease and Drugs to Avoid in Cardiovascular Disease (Chapter 7)

0217-9999-19-112-H04-P

1.5

Group 3 Assessment

3.5

 

Chronic Heart Failure (Chapter 8)

0217-9999-19-144-H01-P

1.5

70%

Acute Decompensated Heart Failure (Chapter 9)

0217-9999-19-145-H01-P

1.5

Cardiac Transplantation and Mechanical Circulatory Support (Chapter 10)

0217-9999-19-146-H01-P

1.5

Group 4 Assessment

4.5

 

Acute Coronary Syndromes (Chapter 11)

0217-9999-19-147-H01-P

1.75

70%

Cardiovascular Emergencies (Chapter 12)

0217-9999-19-148-H01-P

1.5

Group 5 Assessment

3.25

 

Pulmonary Arterial Hypertension (Chapter 13)

0217-9999-19-149-H01-P

1.25

74%

Specialized Topics in Cardiovascular Disease (Chapter 14)

0217-9999-19-150-H01-P

1.25

Pharmacogenomics of Cardiovascular Pharmacotherapies
(Chapter 15)

0217-9999-19-151-H01-P

1.25

Group 6 Assessment

3.75

 

Principles of Information Management and Education: Research Design, Biostatistics,  Literature, and Education and Training (Chapter 16)

0217-9999-19-152-H04-P

 

2.0

74%

Principles of Cardiology Pharmacy Practice Administration: Quality Improvement, Pharmacoeconomics and Safe Medication Use (Chapter 17)

0217-9999-19-153-H04-P

 

1.5

Group 7 Assessment

3.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Learning Objectives

After participating in this CPE activity, leaners should be able to: 

Primary Prevention of Cardiovascular Disease and Public Health (Chapter 1)
ACPE #0217-9999-19-106-H01-P

  • Identify the pharmacotherapeutic agents that reduce the risk of developing cardiovascular disease (CVD).
  • Given a patient scenario, develop a treatment plan that incorporates lifestyle modifications and evidence-based pharmacotherapy to reduce the risk of an index cardiac event.
  • Develop a tobacco cessation plan for a patient who requests assistance for a quit attempt.
  • Describe the role of selecting appropriate statin potency for the primary prevention of CVD.
  • Formulate discussion points that should be incorporated into a patient discussion regarding aspirin use for the primary prevention of CVD.
  • Advise a patient on the most appropriate nonpharmacologic and pharmacotherapeutic options for managing obesity. 

Dyslipidemia (Chapter 2)
ACPE #0217-9999-19-107-H01-P

  • Describe the role of cholesterol and lipoproteins in the development of atherosclerotic cardiovascular disease (ASCVD).
  • Evaluate a patient’s ASCVD risk by appropriately using the 10-year ASCVD Pooled Cohort Equations and optional risk markers.
  • Establish goals of therapy, select an appropriate statin intensity, and create a monitoring plan for patients receiving lipid-lowering therapies for primary and secondary prevention of ASCVD.
  • Develop an appropriate treatment regimen for patients who are statin intolerant or unable to achieve goals of therapy on maximally tolerated statin therapy, according to the 2018 Guideline on the Management of Blood Cholesterol.
  • Identify appropriate indications for the use of triglyceride-lowering therapies to manage hypertriglyceridemia.
  • Evaluate the needs of special populations (e.g., those with diabetes, older adults, those with kidney disease), and adapt treatment strategies to optimize outcomes.

Blood Pressure Management of Adult Patients (Chapter 3)
ACPE #0217-9999-19-108-H01-P

  • Develop an optimal pharmacologic treatment plan for a patient with hypertension (HTN) according to practice guidelines and clinical trial evidence.
  • Demonstrate appropriate drug selection and blood pressure goals for the treatment of HTN according to concomitant conditions and compelling indications.
  • Devise an evidence-based treatment strategy for resistant HTN to achieve blood pressure goals.
  • Construct appropriate drug therapy plans for the treatment of hypotension.

Stable Atherosclerotic Disease (Chapter 4)
ACPE #0217-9999-19-109-H01-P

  • Recommend patient-specific pharmacologic therapy for the management of stable ischemic heart disease (SIHD).
  • Differentiate between the antianginal options for a patient with refractory angina.
  • Develop an optimal pharmacologic regimen and monitoring plan for patients with peripheral arterial disease (PAD) considering individual patient symptomatology and characteristics.
  • Develop an evidence-based pharmacologic regimen for secondary prevention of ischemic stroke and transient ischemic attack (TIA).
  • Recommend risk factor modification strategies to prevent a recurrent event for patients with SIHD, PAD, and ischemic stroke/TIA.

Anticoagulation (Chapter 5)
ACPE #0217-9999-19-110-H01-P

  • Recommend a patient-specific pharmacotherapy plan to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF).
  • Devise an evidence-based pharmacotherapy plan for preventing and treating venous thromboembolism (VTE).
  • Analyze the need for anticoagulant therapy in patients with atrial fibrillation or VTE.
  • Determine appropriate reversal strategies for patients at risk of actively bleeding, or actively bleeding, while receiving oral anticoagulation therapy.
  • Determine appropriate selection and dosing of anticoagulant therapy on the basis of patient-specific factors and drug interactions.
  • Evaluate literature and clinical implications of data for patients receiving anticoagulant agents.

Arrhythmias (Chapter 6)
ACPE #0217-9999-19-111-H01-P

  • Describe the principles of basic electrocardiogram (ECG) interpretation
  • Compare and contrast risk factors for and etiologies, clinical features, signs and symptoms, and goals of therapy of sinus bradycardia, atrial fibrillation (AF), supraventricular tachycardia (SVT) (including Wolff-Parkinson-White [WPW] syndrome), premature ventricular complexes (PVCs) and ventricular tachycardia (VT)
  • Compare and contrast appropriate pharmacologic and nonpharmacologic treatment options for sinus bradycardia, AF, SVT, PVCs, and VT
  • Compare and contrast the mechanisms of action of drugs used for ventricular rate control and conversion to and maintenance of sinus rhythm in patients with AF
  • Describe the risk of thromboembolism in patients with AF and the importance of anticoagulation in this population
  • Compare and contrast nonpharmacologic and pharmacologic methods of terminating SVT
  • Compare and contrast nonpharmacologic and pharmacologic methods for preventing the recurrence of SVT.
  • Describe the management for symptomatic PVCs
  • Compare and contrast nonpharmacologic and pharmacologic methods of terminating VT
  • Compare and contrast nonpharmacologic and pharmacologic methods for preventing the recurrence of VT and reducing the risk of sudden cardiac death.
  • Develop evidence-based patient-specific pharmacotherapy plans for patients with symptomatic sinus bradycardia, AF, SVT (including WPW), PVCs, and VT.
  • Describe common and important drug-drug interactions associated with drugs used for the management of arrhythmias and their complications

Drug Induced Cardiovascular Disease and Drugs to Avoid in Cardiovascular Disease (Chapter 7)
ACPE #0217-9999-19-112-H04-P

  • Identify potential drug-induced cardiovascular diseases.
  • Analyze a medication list to determine causative agents for common drug-induced cardiovascular diseases.
  • Evaluate potential medications that can contribute to the development of torsades de pointes.
  • Review anticancer therapies that cause cardiovascular toxicities.
  • Evaluate patient characteristics and laboratory values to assess the risk of heparin-induced thrombocytopenia and develop an appropriate treatment plan. 

Chronic Heart Failure (Chapter 8)
ACPE #0217-9999-19-144-H01-P

  • Given a patient with heart failure (HF), describe the classifications, staging, clinical presentation, etiologies, and diagnostic considerations.
  • Describe the pathophysiology of HF, focusing on the role that neurohormonal and other vasoactive agents play in HF progression.
  • Given a patient with chronic HF, devise an appropriate pharmacologic and nonpharmacologic therapeutic plan, with an emphasis on guideline-directed therapy and management.
  • Given a patient with chronic HF and several comorbidities, devise an appropriate evidence-based pharmacotherapy plan addressing specific comorbidities related to HF.

Acute Decompensated Heart Failure (Chapter 9)
ACPE #0217-9999-19-145-H01-P

  • Classify a patient with acute decompensated heart failure into a hemodynamic subset on the basis of signs/symptoms, laboratory values, and hemodynamic measures obtained by pulmonary artery catheter monitoring.
  • Design an initial pharmacotherapeutic treatment and monitoring plan for a patient with acute decompensated heart failure based on hemodynamic subset.
  • Devise a modified treatment and monitoring plan in a patient with acute decompensated heart failure and diuretic resistance.
  • Compare and contrast the use of intravenous vasodilators and positive inotropes in the treatment of acute decompensated heart failure, and among the agents within each drug class.
  • List strategies for reducing the risk of heart failure readmission among patients recovering from acute decompensated heart failure.

Cardiac Transplantation and Mechanical Circulatory Support (Chapter 10)
ACPE #0217-9999-19-146-H01-P

  • Evaluate levels of risk in the cardiac transplant candidate.
  • Derive rational peri- and postoperative rejection mitigation strategies in cardiac transplant recipients.
  • Construct safe and effective drug therapy regimens for patients receiving extracorporeal membrane oxygenation support.
  • Devise effective thromboprophylactic strategies or patients receiving percutaneous ventricular assist device support.
  • Design effective treatment plans for patients with complications of durable left ventricular assist device therapy.

Acute Coronary Syndromes (Chapter 11)
ACPE #0217-9999-19-147-H01-P

  • Distinguish between reperfusion strategies for acute coronary syndrome (ACS): ST-segment elevation myocardial infarction (STEMI) and non–ST-segment elevation (NSTE) ACS.
  • Devise a pharmacotherapeutic treatment plan for a patient with a STEMI undergoing primary percutaneous coronary intervention (PCI) and for a patient with an NSTE-ACS undergoing an early invasive or ischemic-guided approach.
  • Differentiate between the best possible pharmacologic options for preventing thrombotic events in the acute management of ACS.
  • Analyze differences in evidence, pharmacology, pharmacokinetics, drug-drug interactions, and adverse events between the P2Y12 inhibitors and anticoagulants used in ACS management.
  • Devise an individualized evidence-based treatment plan for patients in need of secondary prevention post-ACS, including mortality-reducing therapies.

Cardiovascular Emergencies (Chapter 12)
ACPE #0217-9999-19-148-H01-P

  • Choose appropriate management pathways/treatment for a patient with cardiac arrest according to patient presentation.
  • Differentiate between the various categories of shock.
  • Select the optimal management strategies for the various types of shock.
  • Construct a pharmacotherapy regimen for the various hypertensive crises.
  • Select an appropriate management plan for a patient presenting with acute aortic syndrome.
  • Design a pharmacotherapy plan for the management of acute ischemic stroke.

Pulmonary Arterial Hypertension (Chapter 13)
ACPE #0217-9999-19-149-H01-P

  • Describe the classification of pulmonary hypertension and implications for treatment.
  • Discuss the importance of pulmonary arterial hypertension (PAH) pathobiology and the role of various pathways as treatment targets in the development of PAH-specific treatment.
  • Define treatment goals for the management of PAH.
  • Outline targeted medications for PAH, including indications, dosing, monitoring, and their place within current treatment algorithms.
  • Identify common adverse effects and drug interactions associated with PAH medications.
  • Highlight appropriate treatment approaches for the management of decompensated PAH.
  • Design a treatment plan for a patient with PAH.

Specialized Topics in Cardiovascular Disease (Chapter 14)
ACPE #0217-9999-19-150-H01-P

  • Recommend empiric antibiotic therapy for patients with suspected infective endocarditis (IE).
  • Develop a therapeutic plan regarding medication therapy for patients with IE or needing prophylaxis.
  • Identify patients who require IE prophylactic therapy.
  • Develop a treatment plan for patients with pericarditis.
  • Recommend appropriate therapy for patients with myocarditis.
  • Plan a medication therapy regimen for patients with valvular heart disease.

Pharmacogenomics of Cardiovascular Pharmacotherapies (Chapter 15)
ACPE #0217-9999-19-151-H01-P

  • Apply Clinical Pharmacogenetics Implementation Consortium (CPIC) guidance in the clinical setting.
  • Associate clinically actionable genetic polymorphisms with response to cardiovascular pharmacotherapies.
  • For a given patient, estimate therapeutic response to antiplatelet therapy using CYP2C19 genotype information.
  • For a given patient, analyze the impact of the SLCO1B1 genotype on the risk of myopathy with statins.
  • For a given patient, estimate the dose of warfarin using VKORC1 and CYP2C9 genotype information.

Principles of Information Management and Education:  Research Design, Biostatistics, Literature, and Education and Training (Chapter 16)
ACPE #0217-9999-19-152-H04-P

  • Identify different types of data (nominal, ordinal, continuous) to determine the appropriate type of statistical test (parametric vs. nonparametric).
  • Select appropriate statistical tests based on the sample distribution, data type, and study design.
  • Identify the most appropriate study design to answer a given clinical question.
  • Describe the key tenets of internal and external validity in cardiovascular studies.
  • Describe the advantages and disadvantages of surrogate and composite outcomes in cardiovascular studies

Principles of Cardiology Pharmacy Practice Administration: Quality Improvement, Pharmacoeconomics and Safe Medication Use
ACPE #0217-9999-19-153-H04-P

  • Develop policies, procedures, and clinical protocols related to the medication use process.
  • Identify formulary management activities to improve the prescribing of safe, effective, and affordable treatments in an organization.
  • List high-risk medications and medication-related processes that are suited for a medication use evaluation (MUE) and be capable of managing the MUE process.
  • Identify sources of quality measures relevant to your organization and use quality and process improvement methods to achieve optimal outcomes.
  • Describe proper documentation practices for clinical pharmacy services and the need for accurate documentation.
  • Review pharmacoeconomic principles and their application to patient care.
  • Define a pharmacist’s scope of practice and the importance of credentialing and privileging.
  • Compare a medication error, adverse drug event (ADE), adverse drug reaction, and preventable ADE.
  • Design an ADE monitoring program, including committee structure, committee reporting mechanisms, and methods of detecting, reporting, and managing ADEs. 

 

Faculty

William L. Baker, Pharm.D., FCCP, FACC, FAHA
Associate Professor, Department of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, Connecticut 

Scott Bolesta, Pharm.D., FCCP, FCCM, BCPS
Associate Professor, Department of Pharmacy Practice
Nesbit School of Pharmacy, Wilkes University
Wilkes-Barre, Pennsylvania 

James C. Coons, Pharm.D., FCCP,  BCCP
Associate Professor, University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology, UPMC Presbyterian Hospital
PGY2 Cardiology Residency Program Director
Pittsburgh, Pennsylvania 

Rhonda Cooper-DeHoff, Pharm.D., M.S., FCCP, FAHA, FACC
Associate Professor and University Term Professor
Department of Pharmacotherapy and Translation Research and Division of Cardiovascular Medicine
Colleges of Pharmacy and Medicine
Associate Director, Center for Pharmacogenomics
University of Florida
Gainesville, Florida 

Paul P. Dobesh, Pharm.D., FCCP, BCPS, BCCP
Professor of Pharmacy Practice
University of Nebraska Medical Center College of Pharmacy
Omaha, Nebraska 

Steve Dunn, Pharm.D, FAHA, FCCP, BCPS, BCCP
Pharmacy Clinical Coordinator, Heart and Vascular
University of Virginia Health System
Charlottesville, Virginia 

Shannon Finks, Pharm.D., FCCP, FACC, BCPS, BCCP, AHSCP-CHC
Professor, Department of Clinical Pharmacy
University of Tennessee College of Pharmacy
Memphis, Tennessee 

Doug Jennings, Pharm.D., FCCP, FAHA, FACC, FHFSA, BCPS
Clinical Pharmacy Manager, Heart Transplant
New York Presbyterian Hospital
Columbia University Irving Medical Center
New York, New York 

Tracy E. Macaulay, Pharm.D., AACC, BCPS (AQ Cardiology), BCCP
Associate Professor, University of Kentucky College of Pharmacy
Cardiology Clinical Pharmacy Specialist
UK HealthCare
Lexington, Kentucky 

Karen McConnell, Pharm.D., FCCP, BCPS-AQ Cardiology, ASH-CHC
System Director, Clinical Pharmacy Services
Catholic Health Initiatives
Englewood, Colorado 

Carrie Oliphant, Pharm.D., FCCP, BCPS, BCCP, AACC
Global Medical Information Specialist
Med Communications, Inc.
Memphis, Tennessee 

Robert Page II, Pharm.D., MSPH, BCPS (AQ-Cards), BCGP, FCCP, FASHP,  FAHA, FHFSA
Professor, Department of Clinical Pharmacy
Professor, Department of Physical Medicine/Rehabilitation
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado 

Mary Parker, Pharm.D., FCCP, FASHP, BCPS , BCCP
Clinical Pharmacy Specialist-Ambulatory Care
Durham VA Medical Center
Durham, North Carolina 

Brent Reed, Pharm.D., BCPS, BCCP
Associate Professor of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland 

Kelly C. Rogers, Pharm.D., FCCP, FACC, BCCP
Professor, Department of Clinical Pharmacy and Translational Science
University of Tennessee College of Pharmacy
Memphis, Tennessee 

Dustin Spencer, Pharm.D., MBA, BCPS, BCCP
Clinical Director, Cardiopulmonary Diseases
Cardinal Health
Houston, Texas 

James E. Tisdale, Pharm.D., FCCP, FAPhA, FNAP, FAHA, FACC, BCPS-AQ Cardiology
Professor, College of Pharmacy Purdue University
Adjunct Professor, School of Medicine
Indiana University
Indianapolis, Indiana 

Reviewers

The American College of Clinical Pharmacy and the authors would like to thank the following individuals for their reviews of the ACCP/ASHP Cardiology Pharmacy Preparatory Review and Recertification Course. 

Jill S. Borchert, Pharm.D., FCCP, BCPS, BCACP
Professor and Vice Chair
Midwestern University Chicago College of Pharmacy
Downers Grove, Illinois 

Amie Brooks, Pharm.D., FCCP, BCACP
Professor of Pharmacy Practice
Interim Director, Division of Ambulatory Care
St. Louis College of Pharmacy
St. Louis, Missouri 

Katherine P. Cabral, Pharm.D., BCCP, BCPS
Associate Professor
Albany College of Pharmacy and Health Sciences
Clinical Pharmacist
Capital Cardiology Associates
Albany, New York 

Matt Casciano, Pharm.D., BCPS
Clinical Pharmacy Specialist - Pulmonary
University of Colorado Health
Aurora, Colorado 

Judy Cheng, Pharm.D., MPH, FCCP, BCPS-AQ Cardiology
Professor and Interim Chair, Department of Pharmacy Practice
MCPHS University
Clinical Pharmacy Specialist
Brigham and Women’s Hospital
Boston, Massachusetts 

Adam B. Cochrane, Pharm.D., MPH
Organ Transplant Clinical Pharmacy Specialist
Inova Fairfax Hospital
Falls Church, Virginia 

Mary Blanton Covell, Pharm.D., MPH, BCPS, BCCP
Pharmacy Clinical Coordinator
Ephraim McDowell Regional Medical Center
Danville, Kentucky 

James M. Curtis, Pharm.D., BCPS
System Clinical Coordinator
Bronson Health Care Group
Kalamazoo, Michigan 

Anne Denham, Pharm.D., BCPS-AQ Cardiology
Clinical Pharmacy Specialist
Kaiser Permanente Colorado
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado 

Kathleen Faulkenberg, Pharm.D., BCPS
Heart Failure and Heart  Transplant Clinical Pharmacist
Cleveland Clinic, Department of Pharmacy
Cleveland, Ohio 

Vicki Groo, Pharm.D. ASH-CHC
Clinical Associate Professor
Departments of Pharmacy Practice and Medicine
University of Illinois at Chicago
Clinical Pharmacist, Heart Center
University of Illinois Hospital and Health Sciences
Chicago, Illinois 

Augustus Hough, Pharm.D., BCCP, BCPS-AQ Cardiology
Clinical Pharmacy Specialist - Cardiology
Director, PGY2 Cardiology Pharmacy Practice Residency
West Palm Beach VA Medical Center
West Palm Beach, Florida 

Cynthia Jackevicius, Pharm.D., M.Sc., FCCP, FAHA, FCCS, BCCP, BCPS-AQ Cardiology
Professor
Western University of Health Sciences
Senior Adjunct Scientist
Institute for Clinical Evaluative Sciences
Los Angeles, California 

Heather Kertland, Pharm.D., FCSHP
Clinical Pharmacy Specialist
St. Michael’s Hospital
Assistant Professor
University of Toronto
Toronto, Ontario 

Yee Ming Lee, Pharm.D., BCPS
Assistant Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado 

Joel C. Marrs, Pharm.D., BCPS, BCACP, BCCP, CLS, ASH-CHC, FAHA, FASHP, FCCP, FNLA
Associate Professor, Department of Clinical Pharmacy
University of Colorado Anschutz Medical Campus
Aurora, Colorado 

Michael Moranville, Pharm.D., BCCP, BCPS-AQ Cardiology
Clinical Pharmacy Specialist
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania 

Jeremy D. Moretz, Pharm.D., BCPS
University of Health Science Center, Adjunct Assistant Professor
Department of Clinical Pharmacy and Translational Science
Nashville, Tennessee 

Kari L. Olson, Pharm.D., FCCP, BCPS
Clinical Pharmacy Specialist Outcomes Research
Kaiser Permanente National Pharmacy
Associate Clinical Professor
University of Colorado Skaggs School of Pharmacy
Aurora, Colorado 

Robbie Parker, Pharm.D.
Professor
University of Tennessee College of Pharmacy
Department of Clinical Pharmacy and Translational Science
Memphis, Tennessee 

Kerry Pickworth, Pharm.D., FCCP, BCPS-AQ Cardiology
Specialty Practice Pharmacist - Cardiology
Richard M. Ross Heart Hospital
Ohio State University Wexner Medical Center
Associate Clinical Professor
Ohio State University College of Pharmacy
Columbus, Ohio 

Kristen T. Pogue, Pharm.D., BCCP, BCPS-AQ Cardiology
Clinical Pharmacist Specialist, Cardiology
Michigan Medicine, University of Michigan, Department of Pharmacy Services
Adjunct Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan 

Sara Richter, Pharm.D., BCPS
Assistant Professor of Pharmacy Practice
St. Louis College of Pharmacy
Clinical Pharmacy Specialist - Internal Medicine
Barnes-Jewish Hospital
St. Louis, Missouri 

Toni L. Ripley, Pharm.D., FCCP, BCCP, BCPS-AQ Cardiology, ASH-CHC
Professor
University of Oklahoma College of Pharmacy
Clinical Pharmacist
Oklahoma Heart Hospital
Oklahoma City, Oklahoma 

Jo Ellen Rodgers, Pharm.D., BCCP, BCPS
 Associate Director, Clinical Fellowship Programs
DPET Clinical Professor
University of North Carolina Eshelman School of Pharmacy
Durham, North Carolina 

Cynthia A. Sanoski, Pharm.D., FCCP, BCPS
Department Chair and Associate Professor
Jefferson College of Pharmacy
Philadelphia, Pennsylvania 

Nicholas C. Schwier, Pharm.D., BCPS
Assistant Professor
University of Oklahoma College of Pharmacy
Clinical Pharmacy Specialist, Cardiology
Oklahoma University Medical Center
Oklahoma City, Oklahoma 

Nancy L. Shapiro, PharmD, FCCP, BCACP, CACP
Clinical Professor, Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Coordinator and Clinical Pharmacist, Antithrombosis Clinic
University of Illinois Hospital and Health Sciences System 

Andrew J. Smith, Pharm.D., FCCP, BCCP, BCPS
Clinical Associate Professor-UMKC School of Pharmacy
Kansas City, Missouri

Zachary A. Stacy, Pharm.D., M.S., FCCP, BCPS
Associate Professor of Pharmacy Practice
St. Louis College of Pharmacy
Pharmacotherapy Specialist - Cardiology
Mercy Hospital St. Louis
St. Louis, Missouri 

Michael C. Thomas, Pharm.D., FCCP, BCPS
Professor
Samford University McWhorter School of Pharmacy
Birmingham, Alabama 

Benjamin Van Tassell, Pharm.D., FCCP, FAHA, BCPS, ASH-CHC
Associate Professor
Virginia Commonwealth University
Richmond, Virginia 

Barbara S. Wiggins, Pharm.D., FCCP, FAHA, FNLA, BCPS, BCCP, BCCCP, CLS, FACC
Clinical Pharmacy Specialist - Cardiology
Medical University of South Carolina
Adjunct Professor
Medical University of South Carolina School of Pharmacy
Charleston, South Carolina 

Craig Williams, Pharm.D., FNLA, BCPS
Clinical Professor
Oregon State University College of Pharmacy
Associate Professor of Medicine
Oregon State University School of Medicine
Portland, Oregon 

Field Testers

Katherine Aymond, Pharm.D., BCPS, BCCP
Michelle Barcelon
Theodore Berei, Pharm.D., MBA, BCPS, BCCP
Amie Brooks, Pharm.D., FCCP, BCACP
Amy Brewster, Pharm.D., BCPS, BCCP
Katherine Cabral Pharm.D., BCPS, BCCP
Brandon Cave, Pharm..D., BCCP, ASH-CHC
Hua Chen, Pharm.D., BCCP
Johnathan Cicci, Pharm.D, BCPS, BCCP
Jackoline Constantino, Pharm.D. BCCP
James C. Coons, Pharm.D., FCCP, BCCP
Julie Cooper, Pharm.D., BCPS (AQ-Cardiology, BCCP, CPP
Kathryn Matthews Cox, Pharm.D. BCPS, (AQ-Cardiology), BCCP
James Curtis, Pharm.D. BCPS
Paul P. Dobesh, Pharm.D., FCCP, BCPS, BCCP
Amr Fahmi, BCCP
Chyi-Jade Fann, Pharm.D., BCCP
Caitlin Forness, Pharm.D., BCPS, BCCP
Yee Jin Hew, BSc (Pharm), BCCP
Carol Heunisch, Pharm.D., BCPS, BCCP
Kazuhiko Kido, Pharm.D., M.S., BCPS, BCCP
Chloe Kim, Pharm.D., BCPS, BCCP
Christa Kirk, Pharm.D., BCCP
Erin Kohler, Pharm.D., BCCP
Yee Ming Lee, Pharm.D., BCPS
Michelle Lew, Pharm.D., BCPS, BCCP,
Melanie Madorsky, Pharm.D., BCPS, BCCP
Andrew Mardis, Pharm.D., BCPS, BCCP
Kristin Montarella, Pharm.D., BCPS, BCPP
Kelly Moritz, Pharm.D., BCCP, BCPS
Jeremy Moretz, Pharm.D., BCPS
Carrie Oliphant, Pharm.D., FCCP, BCPS, BCCP, AACC
Cassidy Oliver, Pharm.D., BCPS, BCCP
Kari Olson, Bsc(Pharm), Pharm.D., BCPS
Mary Parker, Pharm.D., FCCP, FASHP, BCPS , BCCP
Lieth Quffa, Pharm.D., BCCP
Lisa Rhyne, Pharm.D., BCCP
Dustin Spencer, Pharm.D., MBA, BCPS, BCCP
Azita Hajhosseini Talasaz, Pharm.D., BCPS (AQ- Cardiology), BCCP
Kathy Tang, Pharm.D., BCCP
Nathan Tang, Pharm.D., BCPS, BCCP
Chris Tanski, Pharm.D., BCCP, BCPS
Allison Tenhouse Pharm.D., BCCP
Brandi Thoma, Pharm.D., BCPS, BCCP
Elizabeth Tien, Pharm.D., BCPS, BCCP
Benjamin Van Tassell, BCPS, FCCP, FAHA, ASH-CHC
Brent Vickey, Pharm.D., BCPS, BCCP
Kathryn Weber, Pharm.D., BCPS, BCCP
Barbara Wiggins, Pharm.D., BCPS, BCCP, BCCCP
Kevin Wohlfarth, Pharm.D., BCPS, BCCCP, BCCP
Mike Yaros, Pharm.D., BCPS, BCCP
Joseph Zieminski, Pharm.D., BCCP

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, American College of Clinical Pharmacy and American Society of Health-System Pharmacists require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Received Grant Funding/Research Support: James C. Coons (United Therapeutics), Rhonda Cooper-DeHoff (National Institutes of Health: Pharmacogenetics Discovery- NIGMS PGRN Network and Genetics Implementation NHGRI IGNITE Network), James E. Tisdale (Agency, for Healthcare Quality & Research, American College of Clinical Pharmacy, American Heart Association, Indiana Clinical & Translational Sciences Institute Strategic Research Initiative); Kathleen Faulkenberg (National Institutes of Health), Jo Ellen Rodgers (Novartis), Benjamin Van Tassell (Olatec Therapeutics)
  • Consultant/Member of Advisory Board: Paul Dobesh (Boehringer Ingelheim, Pfizer/BMS Alliance, Janssen Pharmaceuticals, Daiichit Sankyo, Portola Pharmaceuticals; Jo Ellen Rodgers (Novartis), Benjamin Van Tassell (Serpin Pharma)
  • Employee of a Pharmaceutical Company:  Jeremy Moretz ( Otsuka Pharamaceutical Commercialization and Development)
  • Other: Carrie Oliphant, Astra Zeneca (support's company through her work at Med Communications); Yee Ming Lee  (Topic Editor Pharamacogenomics, Dynamed Plus)
  • Member of a Speaker's Bureau: Brandon Cave (Portola Pharmaceuticals)
  • All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ACCP and ASHP.

 

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.